title: [Discrete plasmapheresis for coronary heart disease].
abstract: OBJECTIVE
  To provide a rationale for the expediency and efficiency of discrete plasmapheresis (PA) in the package of therapeutic measures for coronary heart disease (CHD).
  
  
  METHODS
  585 sessions or 120 cycles of low-volume therapeutic PA were performed in 91 patients with CHD. The parameters of blood lipid composition, hemocoagulation, rheology, and endotoxicosis were studied.
  
  
  RESULTS
  Removal of 100% circulating plasma volume per treatment cycle could achieve a significant positive result of abnormally higher homeostatic parameters. The levels of high-density lipoprotein cholesterol, antithrombin III, and albumin did not decrease significantly.
  
  
  CONCLUSIONS
  Low-volume discrete PA is a pathogenetically sound and effective method to affect homeostasis in CHD.
authors.forename: I N
authors.initials: IN
authors.lastname: Solov'eva
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Mikhaĭlov
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Andrianova
mesh_terms: D060050:Angina, Stable / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D000789:Angina, Unstable / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D001794:Blood Pressure / Q000502:physiology; D003911:Dextrans / Q000008:administration & dosage; D005260:Female; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage; D050356:Lipid Metabolism / Q000502:physiology; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010952:Plasma Substitutes / Q000008:administration & dosage; D010956:Plasmapheresis / Q000379:methods*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003911:Dextrans; C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes